Theruvath, Johanna
Menard, Marie
Smith, Benjamin A. H. http://orcid.org/0000-0001-8802-416X
Linde, Miles H. http://orcid.org/0000-0003-2553-2890
Coles, Garry L.
Dalton, Guillermo Nicolas
Wu, Wei
Kiru, Louise
Delaidelli, Alberto
Sotillo, Elena
Silberstein, John L.
Geraghty, Anna C.
Banuelos, Allison
Radosevich, Molly Thomas
Dhingra, Shaurya
Heitzeneder, Sabine
Tousley, Aidan
Lattin, John
Xu, Peng
Huang, Jing
Nasholm, Nicole
He, Andy
Kuo, Tracy C. http://orcid.org/0000-0001-6297-8694
Sangalang, Emma R. B.
Pons, Jaume
Barkal, Amira
Brewer, Rachel E.
Marjon, Kristopher D.
Vilches-Moure, Jose G.
Marshall, Payton L.
Fernandes, Ricardo
Monje, Michelle http://orcid.org/0000-0002-3547-237X
Cochran, Jennifer R. http://orcid.org/0000-0002-6532-9873
Sorensen, Poul H. http://orcid.org/0000-0001-7447-2199
Daldrup-Link, Heike E. http://orcid.org/0000-0002-4929-819X
Weissman, Irving L. http://orcid.org/0000-0002-9077-7467
Sage, Julien http://orcid.org/0000-0002-8928-9968
Majeti, Ravindra http://orcid.org/0000-0002-5814-0984
Bertozzi, Carolyn R. http://orcid.org/0000-0003-4482-2754
Weiss, William A. http://orcid.org/0000-0003-2230-9132
Mackall, Crystal L. http://orcid.org/0000-0001-6323-4304
Majzner, Robbie G. http://orcid.org/0000-0001-6969-8011
Funding for this research was provided by:
Alex’s Lemonade Stand Foundation for Childhood Cancer
Deutsche Krebshilfe (P-91650709)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35-CA231997, R01-CA227942, P01 CA217959, P01 CA217959)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 9 December 2020
Accepted: 10 November 2021
First Online: 13 January 2022
Competing interests
: R.G.M. and C.L.M. are founders of, hold equity in and receive consulting fees from Syncopation Life Sciences. C.L.M. is a founder of, holds equity in and receives consulting fees from Lyell Immunopharma. R.G.M. and E.S. are consultants for Lyell Immunopharma. R.G.M. is a consultant for NKarta, Illumina Radiopharmaceuticals, GammaDelta Therapeutics, Aptorum Group and Zai Labs. J.T. is a consultant for Dorian Therapeutics. C.L.M. has also received consulting fees from NeoImmune Tech, Nektar Therapeutics and Apricity Health and royalties from Juno Therapeutics for CD22-CAR. W.A.W. is a founder of, holds equity in and receives consulting fees from StemSynergy Therapeutics. R.M. is on the Board of Directors of BeyondSpring and the Scientific Advisory Boards of Coherus BioSciences, Kodikaz Therapeutic Solutions and Zenshine Pharmaceuticals. R.M. and I.W. are inventors on several patents related to CD47 cancer immunotherapy that are licensed to Gilead Sciences. J.P. is an employee and shareholder of ALX Oncology, and T.C.K. and E.R.B.S. are shareholders of ALX Oncology. J.S. receives research funding from Stemcentrx/Abbvie and Pfizer and licensed a patent to Forty Seven/Gilead on the use of CD47 blocking strategies in SCLC (with I.W.). C.R.B. is a co-founder of Redwood Biosciences (a subsidiary of Catalent), Enable Biosciences, Palleon Pharmaceuticals, InterVenn Bio, Lycia Therapeutics and OliLux Biosciences and is a member of the Board of Directors of Eli Lilly. J.R.C. is a co-founder and equity holder of xCella Biosciences, Combangio and Trapeze Therapeutics. All other authors declare no competing interests.